Equity Profile

BMRN

BioMarin Pharmaceutical Inc.

Health CareBiotechnology$11.1B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help assess how well BioMarin is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and demand for its products, especially in the competitive biotech industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases. With a market cap of $11 billion, it plays a crucial role in the healthcare sector, particularly in rare disease treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly missing estimates by 2.44%. The stock reacted positively, gaining 2.59% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for BioMarin's upcoming earnings are mixed, with no clear consensus on performance. The company has a history of beating EPS estimates, but recent quarters have shown volatility.

Bull Case

If BioMarin can deliver strong revenue growth and maintain or improve its EPS, it could signal robust demand for its therapies, driving the stock higher.

Bear Case

Conversely, if the company reports disappointing results or fails to provide clear guidance, it could lead to a significant sell-off, especially given the recent earnings misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for BioMarin's key therapies this quarter?

Revenue growth will be a critical indicator of market demand and the effectiveness of BioMarin's sales strategies.

Will management provide guidance on future product launches or pipeline developments?

Any insights into upcoming products could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin's pipeline to drive significant revenue growth, particularly given the recent advancements in gene therapies.

Supporting Evidence

Options are pricing a 15.3% move, but the stock has historically averaged only 2.36% in actual moves.

The company's strong track record of beating EPS estimates could indicate that the market is overly cautious.

Key Risk

If revenue growth comes in below 5%, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for BioMarin's growth against the backdrop of recent earnings volatility.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm strong market demand and support a bullish outlook.

Bear Confirmed If

If revenue growth falls below 5%, it could signal underlying issues in product demand and lead to a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±15.3%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move of over 15%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could see a modest increase of around 2.36% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react cautiously, leading to little change in price.

Miss

A miss on earnings could lead to a decline of approximately 0.37%, reflecting investor disappointment and potential concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of new product launches.
2Details on revenue growth from key therapies.
3Management's outlook on market conditions and competition.
4Insights into the company's pipeline and upcoming clinical trials.
5Any commentary on cost management and operational efficiency.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help assess how well BioMarin is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and demand for its products, especially in the competitive biotech industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly missing estimates by 2.44%. The stock reacted positively, gaining 2.59% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for BioMarin's upcoming earnings are mixed, with no clear consensus on performance. The company has a history of beating EPS estimates, but recent quarters have shown volatility.

Bull Case

If BioMarin can deliver strong revenue growth and maintain or improve its EPS, it could signal robust demand for its therapies, driving the stock higher.

Bear Case

Conversely, if the company reports disappointing results or fails to provide clear guidance, it could lead to a significant sell-off, especially given the recent earnings misses.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for BioMarin's key therapies this quarter?

Revenue growth will be a critical indicator of market demand and the effectiveness of BioMarin's sales strategies.

Will management provide guidance on future product launches or pipeline developments?

Any insights into upcoming products could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin's pipeline to drive significant revenue growth, particularly given the recent advancements in gene therapies.

Supporting Evidence

Options are pricing a 15.3% move, but the stock has historically averaged only 2.36% in actual moves.

The company's strong track record of beating EPS estimates could indicate that the market is overly cautious.

Key Risk

If revenue growth comes in below 5%, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for BioMarin's growth against the backdrop of recent earnings volatility.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm strong market demand and support a bullish outlook.

Bear Confirmed If

If revenue growth falls below 5%, it could signal underlying issues in product demand and lead to a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±15.3%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move of over 15%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could see a modest increase of around 2.36% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may react cautiously, leading to little change in price.

Miss

A miss on earnings could lead to a decline of approximately 0.37%, reflecting investor disappointment and potential concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of new product launches.
2Details on revenue growth from key therapies.
3Management's outlook on market conditions and competition.
4Insights into the company's pipeline and upcoming clinical trials.
5Any commentary on cost management and operational efficiency.